Skip to content

MARKER THERAPEUTICS, INC.: 10-Q filed 2019-08-09

What MARKER THERAPEUTICS, INC. reported in its quarterly report filed 2019-08-09 (fiscal Q2 2019): 30 published measures, 81 facts as tagged in accession 0001144204-19-038714.

This filing

Form
10-Q (quarterly report)
Filed
2019-08-09
Fiscal period
fiscal Q2 2019
Accession
0001144204-19-038714 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MARKER THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-06-3054,995,221USD
At 2018-12-3162,144,310USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2019-06-303,591,433USD
At 2018-12-312,803,572USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-06-3051,403,788USD
At 2019-03-3155,610,912USD
At 2018-12-3159,340,738USD
At 2018-06-304,144,526USD
At 2018-03-31615,959USD
At 2017-12-313,658,127USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2019-06-3053,444,906USD
At 2018-12-3161,746,748USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-5,570,391USD91
2019-01-01 to 2019-06-30-10,889,316USD181
2018-04-01 to 2018-06-30-4,812,797USD91
2018-01-01 to 2018-06-30-8,009,283USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-01-01 to 2019-06-30-8,059,583USD181
2018-01-01 to 2018-06-30-4,745,537USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2019-01-01 to 2019-06-30305,382USD181
2018-01-01 to 2018-06-300USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2019-04-01 to 2019-06-300USD91
2019-01-01 to 2019-06-300USD181
2018-04-01 to 2018-06-30205,994USD91
2018-01-01 to 2018-06-30205,994USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-01-01 to 2019-06-3063,123USD181
2018-01-01 to 2018-06-307,399,210USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2019-01-01 to 2019-06-30-305,382USD181
2018-01-01 to 2018-06-300USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-06-30-316,994,766USD
At 2018-12-31-306,105,450USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2019-04-01 to 2019-06-3045,501,078shares91
2019-01-01 to 2019-06-3045,483,513shares181
2018-04-01 to 2018-06-3011,838,371shares91
2018-01-01 to 2018-06-3011,233,755shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2019-06-30413,239USD
At 2018-12-31147,668USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2019-04-01 to 2019-06-301,363,000USD91
2019-01-01 to 2019-06-302,889,243USD181
2018-04-01 to 2018-06-30960,000USD91
2018-01-01 to 2018-06-301,096,472USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-5,873,565USD91
2019-01-01 to 2019-06-30-11,512,035USD181
2018-04-01 to 2018-06-30-4,673,797USD91
2018-01-01 to 2018-06-30-7,871,283USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-06-3054,034,527USD
At 2018-12-3161,996,642USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-06-303,206,264USD
At 2018-12-312,803,572USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2019-06-301,436,000USD
At 2018-12-311,619,000USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-04-01 to 2019-06-305,873,565USD91
2019-01-01 to 2019-06-3011,512,035USD181
2018-04-01 to 2018-06-304,879,791USD91
2018-01-01 to 2018-06-308,077,277USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-04-01 to 2019-06-303,152,445USD91
2019-01-01 to 2019-06-305,985,140USD181
2018-04-01 to 2018-06-301,826,837USD91
2018-01-01 to 2018-06-303,426,387USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-06-3045,500,000shares
At 2018-12-3145,400,000shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2019-06-30368,353,041USD
At 2018-12-31365,400,748USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2019-06-30547,455USD
At 2019-01-01637,000USD
At 2018-12-310USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2019-06-30580,000USD
At 2019-01-01670,000USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2019-06-30453,000USD
At 2018-12-31148,000USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2019-06-3040,000USD
At 2018-12-310USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2019-04-01 to 2019-06-302,721,120USD91
2019-01-01 to 2019-06-305,526,895USD181
2018-04-01 to 2018-06-303,052,954USD91
2018-01-01 to 2018-06-304,650,890USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2019-04-01 to 2019-06-3029,000USD91
2019-01-01 to 2019-06-3040,000USD181
2018-01-01 to 2018-12-310USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2019-01-01 to 2019-06-3039,811USD181
2018-01-01 to 2018-06-300USD181

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2019-04-01 to 2019-06-30111,000USD91

Inspect the source

Entity
MARKER THERAPEUTICS, INC. / CIK 0001094038
Captured
2026-09-20T05:22:11.393Z
SEC response SHA-256
11a45295baae8ad4450041d3d51c2454c6531734b6bbb806e124ea5eb0db02da

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001094038.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))